Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)

A Double-Blind, Multicenter, Placebo-Controlled Study of MK0869 in the Treatment of Patients With Major Depressive Disorder

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00042029

Enrollment

324

Registered

2002-07-23

Start date

2002-06-18

Completion date

2003-10-03

Last updated

2017-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Brief summary

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.

Detailed description

The duration of treatment is 8 weeks.

Interventions

DRUGMK0869, aprepitant

DRUGComparator: placebo

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients with Major Depressive Disorder

Design outcomes

Primary

Measure	Time frame
HAMD-17 total score; Tolerability	—

Secondary

Measure	Time frame
CGI-I Scale score; Sheehan Disability Scale	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026